Andrew T. Namanja
AbbVie (United States)(US)
Publications by Year
Research Areas
Protein Structure and Dynamics, Signaling Pathways in Disease, Enzyme Structure and Function, Toxin Mechanisms and Immunotoxins, Ubiquitin and proteasome pathways
Most-Cited Works
- → Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts(2012)347 cited
- → Stereospecific gating of functional motions in Pin1(2011)82 cited
- → Insights into High Affinity Small Ubiquitin-like Modifier (SUMO) Recognition by SUMO-interacting Motifs (SIMs) Revealed by a Combination of NMR and Peptide Array Analysis(2011)81 cited
- → Hydroxamic Acid and Benzoic Acid–Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo(2015)73 cited
- → Substrate Recognition Reduces Side-Chain Flexibility for Conserved Hydrophobic Residues in Human Pin1(2007)72 cited
- → Sequence-specific dynamics modulate recognition specificity in WW domains(2007)57 cited
- → Toward Flexibility−Activity Relationships by NMR Spectroscopy: Dynamics of Pin1 Ligands(2010)55 cited
- → Identification and Characterization of a New Chemotype of Noncovalent SENP Inhibitors(2013)43 cited
- → Mapping the dynamics of ligand reorganization via 13CH3 and 13CH2 relaxation dispersion at natural abundance(2009)28 cited
- → Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation(2016)28 cited